Tesamorelin Research Explained: What Studies Show and What to Track

Tesamorelin is one of the few peptides with a clear U.S. prescription label. Sold under brand names such as EGRIFTA SV, it is a growth hormone-releasing factor (GHRF) analog. The FDA approved it to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. That is a narrower indication than many online posts suggest.

This explainer covers what tesamorelin is, what phase 3 research reported, how the label limits its use, and what a careful peptide tracker app should capture if you and your licensed healthcare provider decide it is part of your plan. It is not advice. Whether any medicine fits your situation is a decision for a provider who knows your history.

What tesamorelin is

Tesamorelin is a synthetic analog of human growth hormone-releasing factor. In plain terms, it binds GHRF receptors and stimulates the pituitary to release more of the body's own growth hormone. Higher growth hormone then raises IGF-1. The DailyMed label for EGRIFTA SV describes that mechanism and the approved indication for excess abdominal fat in HIV-associated lipodystrophy. You can read the full prescribing information on DailyMed (EGRIFTA SV).

The same label is clear about what tesamorelin is not for. It is not indicated for weight loss management. Long-term cardiovascular safety has not been established. There are also no data showing that taking it improves how well people stay on antiretroviral therapy. Those limits matter when you read marketing that frames tesamorelin as a general fat-loss peptide.

What phase 3 research reported

Visceral fat in HIV lipodystrophy

Two large multicenter, randomized, double-blind, placebo-controlled phase 3 programs tested tesamorelin in HIV-infected adults with excess abdominal fat. A pooled analysis of those trials, published in The Journal of Clinical Endocrinology and Metabolism, reported that daily tesamorelin reduced visceral adipose tissue (VAT) compared with placebo over 26 weeks, with safety extension data out to longer follow-up. The authors summarized clinically meaningful VAT reduction in that specific population. Details are on PubMed (PMID 20554713).

A related analysis in Clinical Infectious Diseases looked at whether VAT reduction lined up with metabolic changes. Across the phase 3 programs, tesamorelin was associated with about a 15% to 20% drop in visceral adipose tissue over 6 to 12 months in people with HIV-associated abdominal adiposity. When VAT fell, the authors also reported an improved metabolic profile on several lab measures. That paper is on PubMed (PMID 22495074).

What the studies measured

Across the phase 3 work and the label summary, researchers tracked:

• Visceral adipose tissue on CT (the primary efficacy measure)
• Waist circumference and trunk fat
• Lean body mass
• IGF-1 and related markers
• Lipids and glucose-related labs
• Patient-reported distress about belly appearance
• Adverse events, including injection-site reactions, fluid retention symptoms, and glucose changes

Body weight itself was described as roughly weight-neutral in the label discussion. That is one reason the product is not positioned as a general weight-loss drug.

Safety signals called out on the label

The DailyMed prescribing information highlights several monitoring themes that also show up in the trials:

• Rising IGF-1, which needs periodic lab checks
• Fluid retention (edema, joint discomfort, carpal tunnel-type symptoms)
• Glucose intolerance or new diabetes risk in some people
• Injection-site reactions
• Caution around active malignancy and other contraindications listed on the label

Common adverse reactions reported more often than placebo included arthralgia, injection-site erythema and pruritus, pain in extremity, peripheral edema, and myalgia. None of that is a personal prediction for you. It is a reason to keep a dated record and bring questions to your provider.

How to read tesamorelin claims online

Tesamorelin has stronger human evidence than many research peptides, but context still gets lost online. Useful checks:

1. Is the claim about HIV-associated lipodystrophy or about general fat loss? The approved indication and the phase 3 programs were specific.
2. Are they citing VAT (deep abdominal fat) or scale weight? The research story is mainly about visceral fat, not a large drop on the bathroom scale.
3. Do they mention IGF-1 and glucose monitoring? Careful sources do. Overconfident posts often skip labs.
4. Are brand formulations mixed up? Different EGRIFTA formulations are not interchangeable. Reconstitution liquid, storage, and how a vial is prepared can differ. Follow the product your pharmacy dispensed and your provider's instructions.
5. Does the source hedge? Phase 3 data are strong for the labeled use. They do not prove every off-label claim circulating on social media.

What to record if tesamorelin is part of your plan

If you and your licensed provider decide tesamorelin belongs in your care, a clean log helps more than memory. The goal is a packet you can hand over at the next visit.

Dose and timing

Write the dose your provider gave you, exactly as written, plus the date and time you took it. If the schedule changes, note who changed it and when. Do not invent numbers from a forum post.

Vial and reconstitution details

Tesamorelin products are supplied as lyophilized powder that must be mixed before use. Record:

• Which product and strength your pharmacy dispensed
• Which diluent you were told to use (the label product specifies the diluent that comes with that kit)
• How much liquid was added
• Reconstitution date and time
• Whether unused mixed solution was discarded as directed

Those details matter for a clean vial tracker record. The guide to entering your vial and dose walks through why strength and water volume belong next to each other.

When you need to check how vial strength, water added, and the dose your provider gave you translate into syringe units, Peppy's free peptide calculator shows units on a U-100 syringe, volume, strength in mg/mL, and doses per vial. Any pre-filled values in a tool are placeholders, not recommendations. Replace them with what your provider wrote.

Injection sites

The label directs abdominal subcutaneous injection and rotating sites away from scars, bruises, and the navel. Logging each site makes local redness or irritation easier to discuss. See injection site rotation.

How you feel and what labs say

Record side-effect check-ins from mild to severe, especially swelling, joint discomfort, injection-site issues, or anything new. Note lab dates for IGF-1, glucose, and lipids when your provider orders them. A simple severity scale plus dates is more useful than a vague memory weeks later.

Outcomes that match the research

If the goal is excess abdominal fat under HIV care, waist measurements, photos your provider requested, or imaging notes they share are more aligned with the trials than scale weight alone. Keep those next to your dose history so trends are visible in one place. The weight, side effects and history guide covers one practical way to package that for appointments.

Keeping a record in Peppy

A notebook works if you are consistent. A dedicated peptide tracker app can keep doses, vials, sites, reminders, and how you feel together.

Peppy is an iPhone peptide tracker app built for that kind of record. You enter the dose your provider gave you, log shots with dose reminders, track what is left in each vial, and rotate injection sites. Data stays on your iPhone and your own iCloud backup, with no account required. It is free to start; Peppy Premium is a 7-day free trial, then $39.99 a year.

The short version

Tesamorelin is an FDA-approved GHRF analog for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Pooled phase 3 work and follow-up analyses reported meaningful visceral fat reduction in that population, with a roughly weight-neutral effect and important monitoring needs around IGF-1, glucose, fluid retention, and injection sites. It is not labeled for general weight-loss management. Decisions about use belong with a licensed healthcare provider. If tesamorelin is part of your plan, a careful peptide tracker record of doses, reconstitution details, sites, how you feel, and labs is one of the most useful things you can bring to the next visit.